Augmedix appoints William Febbo as new member of its board of directors

[ad_1]

SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) — Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical data and documentation services, today announced that Guillaume Febbogeneral manager and director of OptimizeRxjoined its Board of Directors, effective March 28, 2022.

“We are extremely pleased to welcome Will to our Board of Directors and to leverage his extensive experience in building and managing technology and healthcare companies,” said Manny Krakaris, CEO of Augmedix. “We believe his experience in leading the successful growth and expansion of OptimizeRx will provide valuable insight as we continue on our clear path to unlocking the great market opportunity ahead.”

For 20 years, Mr. Febbo has led companies in health services, technology and finance. He is currently Managing Director and Director of OptimizeRx (Nasdaq: OPRX), and continues to drive healthcare innovation, leading the transformation of OptimizeRx into a leading digital health company that facilitates point-of-care communication for better health outcomes. Mr. Febbo previously served as Chief Operating Officer of Investment Banking at Capital Merriman and CEO of Digital Capital Network (“DCN”), a wholly owned subsidiary of Merriman Holdings. Before Merriman, Mr. Febbo served as CEO and co-founder of MedPanel, a business information and communications provider for the life sciences and financial industries, which was later acquired by Capital Merriman. Mr. Febbo serves as a faculty member for Massachusetts Institute of Technology linQ program, a collaborative initiative increasing the potential of innovative biomedical research for the benefit of society and the economy and also sits on the board of the The United Nations of Greater Boston.

“I am honored to join the Augmedix plank. Augmedix has an impressive track record in driving unique solutions for clinical documentation and solving a significant burden on physicians and healthcare systems,” said Mr. Febbo. “I am also impressed with Augmedix’s technology and progress towards fully automated medical note generation. I look forward to working with this team to continue to leverage the strong momentum of the business and help it achieve its next chapter of growth. »

On Augmedix
Augmedix, Inc. (Nasdaq: AUGX) provides automated medical documentation and data services to large healthcare systems and medical practices, supporting medical offices, clinics, hospitals, emergency services and telemedicine nationwide . The company’s ambient automation platform converts natural conversation between physicians and patients into timely and comprehensive medical notes and runs a suite of related data services. These services relieve physicians of administrative burdens so they can devote more time to patient care. Augmedix’s proprietary platform uses automatic speech recognition, natural language processing, and clinical datasets to capture the ambient conversation of the visit and generate a structured medical note. The structured data from the medical note is then used to provide additional data services. Quality is assured by trained medical documentation specialists. To learn more about Augmedixvisit augmedix.com.

Forward-looking statements

This press release contains “forward-looking statements” that involve a number of risks and uncertainties. Words such as “believes”, “may”, “will”, “estimates”, “potential”, “continues”, “anticipates”, “intends”, “expects”, “could” , “would”, “projects”, “plans”, “goals” and variations of these similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential benefits to Augmedix Mr. Febbo’s appointment to the Board of Directors, Augmedix’s leadership in resolving clinical documentation burden and related issues, and Augmedix’s ability to unlock the great opportunity ahead and continue its growth. Forward-looking statements are based on management’s expectations as of the date hereof and are subject to a number of risks, uncertainties and assumptions, many of which involve factors or circumstances beyond our control. Our actual results could differ materially from those indicated or implied by the forward-looking statements due to a number of factors, including, but not limited to, the factors described in “Risk Factors” and “Discussion and Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our most recent Forms 10-K and 10-Q filed with the Security and Exchange Commissionand similar disclosures in subsequent reports filed with the SECOND. The forward-looking statements included in this press release represent our opinions as of the date of this press release. We assume no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investors:Caroline-PaulGilmartin Group
[email protected]

Media:Kaila GrafemanAugmedix
[email protected]

main logo

Source: Augmedix Inc

2022 GlobeNewswire, Inc., source Press Releases

[ad_2]
Source link

Comments are closed.